Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
暂无分享,去创建一个
[1] J. Schrenzel,et al. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. , 2007, The Journal of investigative dermatology.
[2] D. Mason,et al. A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.
[3] S. H. van der Burg,et al. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.
[4] T. Schumacher,et al. Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.
[5] S. Rosenberg,et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.
[6] H. V. van Boven,et al. Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.
[7] G. Coukos,et al. Immunotherapy for ovarian cancer: what's next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Thiers,et al. Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma , 2009 .
[9] Y. Cho,et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. , 2011, Oral oncology.
[10] S. Dermime,et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.
[11] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[12] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[13] Ton N Schumacher,et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.
[14] Hans-Georg Rammensee,et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. , 2009, Cancer research.
[15] P. Hwu,et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.
[16] Gerd Ritter,et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] Jianhong Cao,et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.
[18] Drew A. Torigian,et al. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.
[19] V. Sondak,et al. Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma , 2012, Journal of immunotherapy.
[20] J. Zeuthen,et al. Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. , 1994, International journal of cancer.
[21] H Nagura,et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.
[22] J. Becker,et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. , 2009, The Journal of clinical investigation.
[23] J. Allison,et al. Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production , 2011, PloS one.
[24] F. Marincola,et al. A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 , 2000, The Journal of Immunology.
[25] J. Becker,et al. T-cell clonotypes in cancer , 2004, Journal of Translational Medicine.
[26] T. Jacks,et al. Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.
[27] C. Huber,et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Donia,et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients , 2012, Journal of Translational Medicine.
[29] Ekaterina S Jordanova,et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. , 2007, Cancer research.
[30] A. Anichini,et al. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. , 1995, Cancer research.
[31] J. Yang,et al. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. , 2012, Cancer research.
[32] C. Aspord,et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.
[33] Mads Hald Andersen,et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. , 2003, Seminars in cancer biology.
[34] P. Romero,et al. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1 , 1995, The Journal of experimental medicine.
[35] W. Clark,et al. Biomarkers for individual susceptibility to carcinogenic agents: excretion and carcinogenic risk of benzo[a]pyrene metabolites. , 1992, Environmental health perspectives.
[36] Mads Hald Andersen,et al. Regulators of apoptosis: suitable targets for immune therapy of cancer , 2005, Nature Reviews Drug Discovery.
[37] V. Reuter,et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.
[38] R. Scolyer,et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Choudhuri,et al. Use of viral promoters in mammalian cell-based bioassays: How reliable? , 2004, Journal of Translational Medicine.
[40] Yoshimasa Tanaka,et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[41] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[42] D. Schadendorf,et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.
[43] S. Qiu,et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.
[44] S. Rosenberg,et al. Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes , 2012, Journal of immunotherapy.
[45] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[46] S. Rosenberg,et al. Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy , 2005, Journal of immunotherapy.
[47] G. Coukos,et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.
[48] C. L. Costantino,et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. , 2009, Journal of the American College of Surgeons.
[49] P. Sinha,et al. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. , 2012, Seminars in cancer biology.
[50] K. R. Daghastanli,et al. HPV16 Tumor Associated Macrophages Suppress Antitumor T Cell Responses , 2009, Clinical Cancer Research.
[51] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.
[52] C. Figdor,et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[53] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[54] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[55] T. Schumacher,et al. Design and use of conditional MHC class I ligands , 2006, Nature Medicine.
[56] J. Schelter,et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[58] J. Schøller,et al. Preferential usage of T‐cell receptor αβ variable regions among tumor‐infiltrating lymphocytes in primary human malignant melanomas , 2007 .
[59] R. Dina,et al. Immunopathology and Infectious Diseases Correlation of CXCL 12 Expression and FoxP 3 Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer , 2010 .
[60] A. Mackensen,et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.
[61] J. Becker,et al. Circulation and homing of melanoma‐reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte‐derived dendritic cells , 2004, International journal of cancer.
[62] E. Angevin,et al. Analysis of T‐cell immune response in renal cell carcinoma: Polarization to type 1‐like differentiation pattern, clonal T‐cell expansion and tumor‐specific cytotoxicity , 1997, International journal of cancer.
[63] B. Baban,et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.
[64] J. Becker,et al. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. , 1999, Journal of immunology.
[65] M. Claesson,et al. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck , 1995, Cancer Immunology, Immunotherapy.
[66] W. Isaacs,et al. Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.
[67] J. Becker,et al. The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase , 2009, PloS one.
[68] F. Marincola,et al. Expansion of Tumor-T Cell Pairs from Fine Needle Aspirates of Melanoma Metastases , 2000, The Journal of Immunology.
[69] L. Steinman,et al. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. , 1990, Science.
[70] I. Svane,et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. , 2011, Blood.
[71] M. Gore,et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] J. Allison,et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.
[73] R. Blasberg,et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.
[74] J. Becker,et al. Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma , 2000, Cancer Immunology, Immunotherapy.
[75] E. Segal,et al. Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.
[76] I. Svane,et al. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. , 2011, Cancer research.
[77] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[78] S. H. van der Burg,et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.
[79] G. Zhu,et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.
[80] W. Dröge,et al. Regulation of T-cell functions by L-lactate. , 1987, Cellular immunology.
[81] S. Rosenberg,et al. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion , 2005, Cancer Immunology, Immunotherapy.
[82] S. Rosenberg,et al. Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma , 2002, The Journal of Immunology.
[83] F. Marincola,et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. , 1998, Journal of immunology.
[84] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[85] C. von Buchwald,et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. , 2011, Cytotherapy.
[86] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[87] J. Becker,et al. Activation of preexisting T cell clones by targeted interleukin 2 therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[88] T. Schumacher,et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients , 2012, Oncoimmunology.
[89] J. Becker,et al. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. , 2004, The Journal of investigative dermatology.
[90] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[92] S. Rosenberg,et al. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. , 1996, The cancer journal from Scientific American.
[93] A. Akbar,et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo , 2006 .
[94] J. Becker,et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.
[95] J. Becker,et al. In situ T cells in melanoma , 1999, Cancer Immunology, Immunotherapy.
[96] J. Becker,et al. In situ cytokine therapy: redistribution of clonally expanded T cells , 2001, European Journal of Immunology.
[97] H. von der Maase,et al. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] P. Coulie,et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.
[99] S. H. van der Burg,et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.
[100] B. Shalmon,et al. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.
[101] R. Kiessling,et al. Tumor‐induced changes in the phenotype of blood‐derived and tumor‐associated T cells of early stage breast cancer patients , 2012, International journal of cancer.
[102] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[103] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[104] G. D. de Bock,et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.
[105] Jeffrey E. Lee,et al. Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients , 2012, Clinical Cancer Research.
[106] J. Becker,et al. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. , 2000, Clinical immunology.
[107] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[108] Polly Matzinger,et al. Tissue-based class control: the other side of tolerance , 2011, Nature Reviews Immunology.
[109] V. Bronte,et al. Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.
[110] Gregor Rothe,et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.
[111] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[112] M. Donia,et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. , 2013, The Journal of investigative dermatology.
[113] P. Straten,et al. Comment on “Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression” , 2009, The Journal of Immunology.
[114] F. Garrido,et al. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank , 2009, Cancer Immunology, Immunotherapy.
[115] D. Speiser,et al. Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients1 , 2000, The Journal of Immunology.
[116] A. Ghahary,et al. High expression of IMPACT protein promotes resistance to indoleamine 2,3‐dioxygenase‐induced cell death , 2010, Journal of cellular physiology.
[117] C. Ahonen,et al. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation , 2012, The Journal of experimental medicine.
[118] Olga K Afanasiev,et al. Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood , 2011, Clinical Cancer Research.
[119] D. Munn,et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. , 2009, Blood.